BioSpectrum India: BioPharma, Healthcare, healthscience, Biotechnology, BioIT, Pharma news updates

SCIENCE

Science | 16 September 2021 | News

ASU paves way for cancer treatment with Hippo pathway genes

A team of researchers from Gurugram-based Apeejay Stya University (ASU)’s Biotech department, including ...Read more

OPINION

Opinion | 22 September 2021 | Views

Relying more on medicinal plants than drugs for diabetes care

Diabetes, one of the most gravitating chronic diseases in the world has taken lead to various advancements in ...Read more

ANALYSIS

Analysis | 21 September 2021 | Views

Managing hazardous, toxic by-products during a pandemic

Waste and its disposal are considered as one of the biggest modern-day issues affecting our world. Millions of...Read more

START-UPS

Start-ups | 24 September 2021 | Features

Click here to view the 'Startup' of the Day!

  We are happy to share with you that BioSpectrum has come up with a brand new opportunity for startups....Read more

SUPPLIER

Supplier | 23 September 2021 | News

Thermo Fisher launches world’s first net zero mass spectrometer

The launch of the world’s first net zero mass spectrometer (MS) will make it easier than ever for scient...Read more

PEOPLE

People | 23 September 2021 | News

Healthium Medtech appoints Ajay Gupta and Namrata Kaul on board

Healthium Medtech has announced the elevation of board member Ajay Gupta to the Chairman of the Board and has ...Read more

ACADEMICS

Academics | 23 September 2021 | News

Taylor & Francis Group partners with IIT-M for AI, data science research

UK-based Taylor & Francis Group has partnered with Robert Bosch Centre for Data Science and Artificial Int...Read more

BLOGS

Blogs | 13 August 2021 | Views

Fertility struggles with COVID-19

With ongoing studies and research there is enough evidence that COVID-19 does have an impact on male and femal...Read more

Videos

Inside Magazine

GUNG-HO PHARMA R&D INVESTMENTS SURPASS $3B

While the pharmaceutical industry helped combat COVID-19, from R&D actions on potential treatment strategies to balancing the medicines supply chain in the time of crisis, it struggled to maintain the natural market flow. As a result, many pharma companies had to abort some of their ongoing R&D investment plans. However for FY20-21, the average R&D expenses constituted 7.2 per cent of the total revenues of the pharma companies, with Lupin, Alembic Pharma and Dr. Reddy’s spending more than others.

The cumulative R&D expenditure of the leading 10 pharma companies has been around Rs 10,627 crore ($1.43 billion) in the previous fiscal. This figure eventually reaches an approximate amount of Rs 22,500 crore ($3.03 billion) after considering the cumulative expenditure by other small and medium players of the India pharma industry

For Feedback, please email us at : communications@mmactiv.com

BioSpectrum Infomercial